General Information of Drug Transporter (DT)
DT ID	DTD0035 Transporter Info
Gene Name	SLC30A8
Protein Name	Zinc transporter 8
Gene ID	169026
UniProt ID	Q8IWU4
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs13266634
Site of GPD	chr8:117172544 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>T
Minor Allele Frequency	T=0.2552/1278 (Global)
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:           7 Drugs in Total
Repaglinide	Drug Info	Diabetes Mellitus	Correlated with the increased drug response in patients (compare with genotype CC)		[ 1]
Zinc Acetate	Drug Info	Healthy Individuals	Correlated with the increased drug response in healthy individuals (compare with genotype CC)		[ 2]
Insulin recombinant	Drug Info	Healthy Individuals	Correlated with the increased drug response in healthy individuals (compare with genotype CC)		[ 2]
Insulin Recombinant	N.A.	Asthma	Genotypes CT + TT is associated with increased response to insulin recombinant and zinc acetate in healthy individuals as compared to genotype CC.		[ 2]
Zinc Acetate	N.A.	Asthma	Genotypes CT + TT is associated with increased response to insulin recombinant and zinc acetate in healthy individuals as compared to genotype CC.		[ 2]
Repaglinide	N.A.	Asthma	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 1]
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC.		[ 1]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Metformin	N.A.	Asthma	Allele C is not associated with response to metformin in people with high risk of developing diabetes as compared to allele T.		[ 3]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the CC genotype may have decreased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.		[ 1]
Insulin Recombinant	N.A.	Diabetes Mellitus, Type 2	Individuals with the CC genotype may have a decreased response to insulin supplemented with zinc acetate as compared to individuals with the CT and TT genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.		[ 2]
Zinc Acetate	N.A.	Diabetes Mellitus, Type 2	Individuals with the CC genotype may have a decreased response to insulin supplemented with zinc acetate as compared to individuals with the CT and TT genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.		[ 2]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the CT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.		[ 1]
Insulin Recombinant	N.A.	Diabetes Mellitus, Type 2	Individuals with the CT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.		[ 2]
Zinc Acetate	N.A.	Diabetes Mellitus, Type 2	Individuals with the CT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.		[ 2]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Repaglinide	N.A.	Diabetes Mellitus, Type 2	Patients with the TT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.		[ 1]
Insulin Recombinant	N.A.	Diabetes Mellitus, Type 2	Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.		[ 2]
Zinc Acetate	N.A.	Diabetes Mellitus, Type 2	Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.		[ 2]
Genetic Polymorphism	rs16889462
Site of GPD	chr8:117172545 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.9510/1882 (Global)
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Repaglinide	N.A.	Asthma	Genotype AG is associated with increased efficacy when treated with repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.		[ 1]
References
1	Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol. 2010 Dec;66(12):1207-15.
2	Effect of zinc supplementation on insulin secretion: interaction between zinc and SLC30A8 genotype in Old Order Amish. Diabetologia. 2015 Feb;58(2):295-303.
3	Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program. Diabetologia. 2011 Oct;54(10):2570-4.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.